RankAlpha logo
Back to Rankings

KYTX

Kyverna TherapeuticsB
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
View Chart

Operating peers and competitors

Source-backed product markets and frozen research comparisons. Valuation comparators remain in the existing peer table.

Loading market evidence...

Research comparisons do not establish forecast usefulness or trading returns.

Compare shared product markets

Membership only; no portfolio weights or estimated losses.

+
Peers tracked
10
U.S. public peers
Grade Position
Above peers
vs peer average
KYTX vs peer average
80/100
KYTX vs. peer average (B vs. D)
Grade spread
A 1 · C 2 · D 3 · F 4
Graded peers loaded
Coverage
10 graded
100% of tracked

Peer overview

RNAC is the first available peer comparator.

Direct Phase 3 myasthenia gravis cell-therapy comparator: Cartesian is studying Descartes-08 in its AURORA trial. Its BCMA-targeted, mRNA-based CAR-T approach and dosing differ materially from Kyverna's CD19-directed miv-cel, limiting valuation comparisons. [Cartesian company release](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-reports-second-quarter-2026-financial)

✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
Top peerRNACCartesian Therapeutics
KYTX
Kyverna Therapeutics
RNAC
Cartesian Therapeutics
Grade
B
C
Momentum
10
12
Value
41
41
Sentiment
86
72
Setup Bias
Net —
-
Market Cap
-
-
Posture
Constructive
Mixed
Open Side-by-Side ComparisonCompare top peers (up to 3)

Grade position vs RNAC

KYTX / RNAC
Grade Position
Above peers
KYTX vs. peer average (B vs. D)
80/100
Momentum
10
RNAC
Value
41
KYTX
Sentiment
86
KYTX

Rotation landscape

Peers ranked by the order returned from the peer source, with grades from the API.

Rank
Ticker
Company
Grade
Grade score
vs KYTX
1
RNAC
RNAC
C
60/100
-1
2
CABA
CABA
A
100/100
+1
3
SRZN
Surrozen Inc Common
F
20/100
-3
4
RLMD
Relmada Therapeutics Inc Common
D
40/100
-2
5
EBS
Emergent BioSolutions Inc Common
D
40/100
-2
RNAC is the first peer returned for this comparison set.